Cited by 562Retinal Diseases and TreatmentsRetinal and Macular SurgeryOcular Diseases and Behçet’s Syndrome

The DOI matches its Crossref record; 9 of the 10 references it cites were found in a registry or an index.

Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results

Open access

Elman, Michael J., Ayala, Allison, Bressler, Neil M., Browning, David, Flaxel, Christina J., Glassman, Adam R., Jampol, Lee M., Stone, Thomas W.·2015·Ophthalmology

DOI 10.1016/j.ophtha.2014.08.047PMC PMC4520307

Open this paper in CoChat — free account

Abstract

Objective To report 5-year results from a previously reported trial evaluating intravitreal 0.5 mg ranibizumab with prompt versus deferred (for ≥24 weeks) focal/grid laser treatment for diabetic macular edema (DME).Design Multicenter, randomized clinical trial.Participants Among participants from the trial with 3 years of follow-up who subsequently consented to a 2-year extension and survived through 5 years, 124 (97%) and 111 (92%) completed the 5-year visit in the prompt and deferred groups, respectively.Methods Random assignment to ranibizumab every 4 weeks until no longer improving (with resumption if worsening) and prompt or deferred (≥24 weeks) focal/grid laser treatment.Main outcome measures Best-corrected visual acuity at the 5-year visit.Results The mean change in visual acuity letter score from baseline to the 5-year visit was +7.2 letters in the prompt laser group compared with +9.8 letters in the deferred laser group (mean difference, -2.6 letters; 95% confidence interval, -5.5 to +0.4 letters; P = 0.09). At the 5-year visit in the prompt versus deferred laser groups, there was vision loss of ≥10 letters in 9% versus 8%, an improvement of ≥10 letters in 46% versus 58%, and an improvement of ≥15 letters in 27% versus 38% of participants, respectively. From baseline to 5 years, 56% of participants in the deferred group did not receive laser. The median number of injections was 13 versus 17 in the prompt and deferral groups, including 54% and 45% receiving no injections during year 4 and 62% and 52% receiving no injections during year 5, respectively.Conclusions Five-year results suggest focal/grid laser treatment at the initiation of intravitreal ranibizumab is no better than deferring laser treatment for ≥24 weeks in eyes with DME involving the central macula with vision impairment. Although more than half of eyes in which laser treatment is deferred may avoid laser for at least 5 years, such eyes may require more injections to achieve these results when following this protocol. Most eyes treated with ranibizumab and either prompt or deferred laser maintain vision gains obtained by the first year through 5 years with little additional treatment after 3 years.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ophtha.2014.08.047

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Linear Mixed Models for Longitudinal Data
Verbeke, G. (1997) · Lecture Notes in Statistics · doi:10.1007/978-1-4612-2294-1_3 · Cited by 3,506
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema
Elman, M. J., Aiello, L. P., Beck, R. W., Bressler, N. M., Bressler, S. B., Edwards, A. R., Ferris, F. L., Friedman, S. M., Glassman, A. R., Miller, K. M., et al. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.031 · Cited by 1,431
Self-citation
The RESTORE Study
Mitchell, P., Bandello, F. M., Schmidt-Erfurth, U. M., Lang, G. E., Massin, P., Schlingemann, R. O., Sutter, F., Simader, C., Burian, G., Gerstner, O., et al. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.01.031 · Cited by 1,344
Expanded 2-Year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema
Elman, M. J., Bressler, N. M., Qin, H., Beck, R. W., Ferris, F. L., Friedman, S. M., Glassman, A. R., Scott, I. U., Stockdale, C. R., & Sun, J. K. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.12.033 · Cited by 572
Self-citation
Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment
Elman, M. J., Qin, H., Aiello, L. P., Beck, R. W., Bressler, N. M., Ferris, F. L., Glassman, A. R., Maturi, R. K., & Melia, M. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.08.022 · Cited by 322
Self-citation
Mixed models for longitudinal data
Cecílio‐Fernandes, D., Tio, R. A., & Jaarsma, D. A. D. C. (2016) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 118
Reproducibility of Spectral-Domain Optical Coherence Tomography Retinal Thickness Measurements and Conversion to Equivalent Time-Domain Metrics in Diabetic Macular Edema
Bressler, S. B., Edwards, A. R., Chalam, K. V., Bressler, N. M., Glassman, A. R., Jaffe, G. J., Melia, M., Saggau, D. D., & Plous, O. Z. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.1698 · Cited by 105
Self-citation
Inference for the Marginal Model
(2009) · Springer series in statistics · doi:10.1007/978-1-4419-0300-6_6 · Cited by 6

Show all 10 references

Sorted by citations

Items 301–400 of 560

Saudi Arabia Guidelines for diabetic macular edema
AlQahtani, A. S., Hazzazi, M. A., Waheeb, S. A., Semidey, V. A., Semidey, V. A., Elgendy, H. M. K., Al-Khars, W., Abouammoh, M. A., & Al-Dhibi, H. A. (2021) · Saudi Medical Journal · doi:10.15537/smj.2021.2.25623 · Cited by 13
Dexamethasone intravitreal implants for diabetic macular edema refractory to ranibizumab monotherapy or combination therapy
Gutiérrez-Benítez, L., Millan, E. G., Arias, L., Garcia, P., Cobos, E., & Caminal-Caramés, M. (2015) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2015.10.019 · Cited by 13
Vitrectomy in Diabetic Macular Edema
Nawrocka, Z., & Nawrocki, J. (2022) · Ophthalmology Science · doi:10.1016/j.xops.2022.100207 · Cited by 15
Peripapillary RNFL thickness in nonexudative versus chronically treated exudative age-related macular degeneration
Yau, G. L., Bell, C. M., Li, C., & Sharma, S. (2015) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2015.01.008 · Cited by 13
Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials
Holden, S. E., Kapik, B. M., Beiderbeck, A. B., & Currie, C. J. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1560779 · Cited by 13
Healthcare Utilization and Treatment Patterns in Diabetic Macular Edema in Korea: a Retrospective Chart Review
Park, K. H., Kim, Y. Y., Jo, Y. J., Oh, J., Lee, J. E., Lee, J. E., Park, D. H., Kang, S. W., Lee, W. K., Kim, H. K., et al. (2019) · Journal of Korean Medical Science · doi:10.3346/jkms.2019.34.e118 · Cited by 13
Pro Re Nata Dexamethasone Implant for Treatment-Naive Phakic Eyes with Diabetic Macular Edema
Bilgic, A., Sudhalkar, A. A., Kodjikian, L., Vasavada, V. A., Vasavada, S. A., Bhojwani, D., Vasavada, V. A., & Srivastava, S. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.05.027 · Cited by 13
Efficacy of One-Year Treatment with Aflibercept for Diabetic Macular Edema with Practical Protocol
Kaiho, T., Oshitari, T., Tatsumi, T., Takatsuna, Y., Arai, M., Shimizu, N., Sato, E., Baba, T., & Yamamoto, S. (2017) · BioMed Research International · doi:10.1155/2017/7879691 · Cited by 12
Predictive factors of outcome of selective retina therapy for diabetic macular edema
Yamamoto, M., Miura, Y., Hirayama, K., Kohno, T., Kabata, D., Theisen‐Kunde, D., Brinkmann, R., & Honda, S. (2020) · International Ophthalmology · doi:10.1007/s10792-020-01288-6 · Cited by 12
Macular laser photocoagulation in the management of diabetic macular edema: Still relevant in 2020?
Wu, L., Zas, M., Cotic, M., Wu, M. B. H., & Wu, A. (2020) · Taiwan Journal of Ophthalmology · doi:10.4103/tjo.tjo_16_20 · Cited by 12
Comparison of 2-Year Outcomes between Intravitreal Ranibizumab and Intravitreal Aflibercept for Diabetic Macular Edema with “Treat-and-Extend” Regimen—Its Usefulness and Problems
Chujo, S., Sugimoto, M., Sasaki, T., Matsui, Y., Kato, K., Ichio, A., Miyata, R., Matsubara, H., & Kondo, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092848 · Cited by 12
Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland
Zirpel, J. J., Pfister, I. B., Gerhardt, C., & Garweg, J. G. (2021) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-021-05187-z · Cited by 12
Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies
Midena, E., Gillies, M. C., Katz, T. A., Metzig, C., Lu, C., & Ogura, Y. (2018) · Journal of Ophthalmology · doi:10.1155/2018/3640135 · Cited by 12
Visual Acuity Outcomes in Diabetic Macular Edema With Fluocinolone Acetonide 0.2 μg/Day Versus Ranibizumab Plus Deferred Laser (DRCR Protocol I)
Singer, M. A., Miller, D. M., Gross, J. G., Greven, C. M., Kapik, B. M., Bailey, C., Ghanchi, F. D., & Kuppermann, B. D. (2018) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20180831-08 · Cited by 12
Revisiting pars plana vitrectomy in the primary treatment of diabetic macular edema in the era of pharmacological treatment
Wu, L., Flikier, S., & Wu, A. (2019) · Taiwan Journal of Ophthalmology · doi:10.4103/tjo.tjo_61_19 · Cited by 12
Real-world outcomes of two-year Conbercept therapy for diabetic macular edema
Cheng, Y., Zhao, M., & Qian, T. (2021) · International Journal of Ophthalmology · doi:10.18240/ijo.2021.03.14 · Cited by 12
Practical Lessons from Protocol I for the Management of Diabetic Macular Edema
Mukkamala, L. K., Bhagat, N., & Zarbin, M. A. (2017) · Developments in ophthalmology · doi:10.1159/000459692 · Cited by 12
Targeting the Effect of VEGF in Diabetic Macular Edema
Wells, J. A., Glassman, A. R., & Jampol, L. M. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1505684 · Cited by 12
Self-citation
Photocoagulation or sham laser in addition to conventional anti-VEGF therapy in macular edema associated with TelCaps due to diabetic macular edema or retinal vein occlusion (TalaDME): a study protocol for a multicentric, French, two-group, non-commercial, active-control, observer-masked, non-inferiority, randomized controlled clinical trial
Dupas, B., Castro‐Farías, D., Girmens, J., Eginay, A., Couturier, A., Villeroy, F., Delyfer, M., Creuzot-Garcher, C. P., Giocanti‐Auregan, A., Beral, L., et al. (2024) · Trials · doi:10.1186/s13063-024-07994-1 · Cited by 11
Renal Biomarkers for Treatment Effect of Ranibizumab for Diabetic Macular Edema
Lai, I. P., Huang, W., Yang, C., Yang, C., Ho, T., & Hsieh, Y. (2020) · Journal of Diabetes Research · doi:10.1155/2020/7239570 · Cited by 10
The clinical utility of aflibercept for diabetic macular edema
Stewart, M. W. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s72792 · Cited by 12
Current intravitreal pharmacologic therapies for diabetic macular edema
Colucciello, M. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1052523 · Cited by 11
En Face Spectral-Domain Optical Coherence Tomography Imaging of Outer Retinal Hard Exudates in Diabetic Macular Edema Based on Optical Coherence Tomography Patterns
Kim, Y., Yu, S., & Kwak, H. W. (2016) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20160324-02 · Cited by 11
Ranibizumab Pretreatment in Vitrectomy with Internal Limiting Membrane Peeling on Diabetic Macular Edema in Severe Proliferative Diabetic Retinopathy
Guan, J., Cai, N., Liu, L.-M., Zhao, N., & Liu, N. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00822-0 · Cited by 11
Microperimetry and mfERG as functional measurements in diabetic macular oedema undergoing intravitreal ranibizumab treatment
Santos, A. R., Raimundo, M., Alves, D., Lopes, M., Pestana, S., Figueira, J., Cunha-Vaz, J. G., & da Silva, R. M. (2020) · Eye · doi:10.1038/s41433-020-1054-2 · Cited by 11
A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema
Lois, N., Gardner, E., McFarland, M., Armstrong, D., McNally, C., Lavery, N. J., Campbell, C., Kirk, R. I., Bajorunas, D. R., Dunne, A. N., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072225 · Cited by 12
Cellular targets in diabetic retinopathy therapy
Rodríguez, M. L., Millán, I., & Ortega, Á. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i9.1442 · Cited by 12
Efficacy and safety of suprachoroidal triamcinolone acetonide in cases of resistant diabetic macular edema
Tayyab, H., Chaudhry, N., & Sadiq, M. A. A. (2019) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.36.1.1194 · Cited by 11
Long-Term Change in Renal Function After Intravitreal Anti-VEGF Treatment for Diabetic Macular Edema: A 2-Year Retrospective Cohort Study
Fang, Y.-C., Lai, I. P., Lai, T., Chen, T., Yang, C., Ho, T., Yang, C., & Hsieh, Y. (2023) · Ophthalmology and Therapy · doi:10.1007/s40123-023-00771-4 · Cited by 10
The effects of anti-vascular endothelial growth factor agents on human retinal pigment epithelial cells under high glucose conditions
Oh, J. R., Han, J. W., Kim, Y. K., Ohn, Y.-H., & Park, T. K. (2017) · International Journal of Ophthalmology · doi:10.18240/ijo.2017.02.04 · Cited by 10
THREE-YEAR TREATMENT OUTCOMES OF AFLIBERCEPT VERSUS RANIBIZUMAB FOR DIABETIC MACULAR EDEMA
Gabrielle, P., Nguyen, V., Creuzot-Garcher, C. P., Arnold, J. J., Mehta, H., Duran, M. A., Bougamha, W., Carreño, E., Viola, F., Squirrell, D., et al. (2022) · Retina · doi:10.1097/iae.0000000000003428 · Cited by 14
Effect of age on response to anti-VEGF agents in patients with center involving diabetic macular edema in a tertiary hospital
Alshalan, H. A., Arévalo, J. F., Alomary, S. I., Ardah, H. I., & Hazzazi, M. A. (2022) · International Journal of Retina and Vitreous · doi:10.1186/s40942-022-00434-9 · Cited by 10
Enface Thickness Mapping and Reflectance Imaging of Retinal Layers in Diabetic Retinopathy
Francis, A. W., Wanek, J. M., Lim, J. I., & Shahidi, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0145628 · Cited by 10
Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy
Bandello, F. M., Corvi, F., Spina, C. L., Benatti, L., Querques, L., Capuano, V., Naysan, J., Chen, X., Sarraf, D., Parodi, M. B., et al. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-308400 · Cited by 10
Clinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema: a review of the current literature
Saedon, H., Anand, A., & Yang, Y. C. (2017) · Clinical ophthalmology · doi:10.2147/opth.s131165 · Cited by 10
Diabetic macular edema, innovative technologies and economic impact: New opportunities for the Lombardy Region healthcare system?
Foglia, E., Ferrario, L. B., Bandello, F. M., Ferri, C., Figini, I., Franzin, M., Gambaro, G., Introini, U., Medaglia, M., Staurenghi, G., et al. (2017) · Acta Ophthalmologica · doi:10.1111/aos.13620 · Cited by 10
Kostenvergleich zugelassener intravitrealer Therapien bei nicht ausreichend auf primäre Therapie ansprechendem diabetischem Makulaödem mit fovealer Beteiligung in Deutschland
Neubauer, A. S., Haritoglou, C., & ULBIG, M. W. (2018) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/s-0043-125076 · Cited by 10
Bevacizumab versus triamcinolone for persistent diabetic macular edema: a randomized clinical trial
Rodrigues, M. W., Cardillo, J. A., Messias, A. M. V., Siqueira, R. C., Scott, I. U., & Jorge, R. (2019) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-019-04564-z · Cited by 10
Effect of Laser Wavelength on Delivering Appropriate Laser Burns through the Opaque Lens Using a Pattern Scan Laser
Hirano, T., Iesato, Y., Imai, A., Toriyama, Y., Kikushima, W., & Murata, T. (2014) · Ophthalmic Research · doi:10.1159/000357918 · Cited by 10
One-Year Anti-VEGF Therapy Outcomes in Diabetic Macular Edema Based on Treatment Intensity
Mehta, H., Gabrielle, P., Hashimoto, Y., Kibret, G. D., Arnold, J., Guillaumie, T., Kheir, W. J., Kok, G., Vujosevic, S., O’Toole, L., et al. (2024) · Ophthalmology Retina · doi:10.1016/j.oret.2024.04.008 · Cited by 9
Long-term results of a single injection of intravitreal dexamethasone as initial therapy in diabetic macular edema
Mahapatra, S. K., & Kumari, S. (2020) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_620_19 · Cited by 9
Three-year treatment outcomes of Aflibercept versus Ranibizumab for diabetic macular edema:: Data from the Fight Retinal Blindness! Registry
Gabrielle, P., Nguyen, V., Creuzot-Garcher, C. P., Arnold, J., Mehta, H., Durán, M. A., Bougamha, W., Carreño, E., Viola, F., Squirrell, D., et al. (2022) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-220298 · Cited by 9
Real-World Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in Türkiye: MARMASIA Study Group Report No. 1
Yayla, U., Sevik, M. O., Karabas, V. L., Şahin, Ö., Özkaya, A., Yenerel, N. M., Öncel, B., Kaplan, F. B., Tokuç, E. Ö., Kanar, H. S., et al. (2023) · Turkish Journal of Ophthalmology · doi:10.4274/tjo.galenos.2023.56249 · Cited by 9
Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario – The BRADIR study
Chakraborty, D., Sharma, A., Mondal, S., Sheth, J. U., Sinha, T. K., Boral, S. K., Mukherjee, A., Bhattacharya, R., & Maitra, R. (2024) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2024.102152 · Cited by 9
Validity of Self-Report in Type 1 Diabetic Subjects for Laser Treatment of Retinopathy
Grassi, M. A., Sun, W., Gangaputra, S. S., Cleary, P. A., Hubbard, L. D., Lachin, J. M., Gao, X., Kiss, S., Barkmeier, A. J., Almony, A., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.06.002 · Cited by 9
Efficacy of Conversion to Aflibercept for Diabetic Macular Edema Previously Refractory to Bevacizumab or Ranibizumab: A Meta-analysis of High-Quality Nonrandomized Studies
Xiao, K., Li, F., Liang, S., Wang, J., Qian, C., & Wan, G. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020904358 · Cited by 9
Determinants in Initial Treatment Choice for Diabetic Macular Edema
VanderBeek, B. L., Scavelli, K., & Yu, Y. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.05.016 · Cited by 9
Comparisons of One to Three Monthly Injections of Aflibercept for Diabetic Macular Edema by Practical Protocol
Hayashi, Y., Tatsumi, T., Oshitari, T., Kaiho, T., Takatsuna, Y., Arai, M., Baba, T., & Yamamoto, S. (2021) · Journal of Diabetes Research · doi:10.1155/2021/1374891 · Cited by 9
Optical Coherence Tomography Biomarkers Predict the Long-Term Restorative Effect of Early Anti-VEGF Treatment on Diabetic Macular Edema
Okudan, S., Duyan, Ş. A., Erdem, A., Oflaz, A. B., & Öztürk, B. (2025) · Life · doi:10.3390/life15020269 · Cited by 8
Short-term effects of intravitreal ranibizumab therapy on diabetic macular edema
Minami, Y., Nagaoka, T., Ishibazawa, A., & Yoshida, A. (2017) · BMC Ophthalmology · doi:10.1186/s12886-017-0420-8 · Cited by 8
Differential Expression of BDNF and BIM in Streptozotocin-induced Diabetic Rat Retina After Fluoxetine Injection
Kim, S. T., Chung, Y. Y., Hwang, H.-I., Shin, H., CHOI, R., & JUN, Y. H. (2021) · In Vivo · doi:10.21873/invivo.12398 · Cited by 8
Effectiveness of microperimetry in evaluating anti-vascular endothelial growth factor therapy for diabetic macular edema patients with relatively good vision
Sugimoto, M., Wakamatsu, Y., Miyata, R., Kato, K., Matsubara, H., & Kondo, M. (2021) · Medicine · doi:10.1097/md.0000000000028404 · Cited by 8
Comparison of 55° Wide-Field Spectral Domain Optical Coherence Tomography and Conventional 30° Optical Coherence Tomography for the Assessment of Diabetic Macular Edema
Munk, M. R., Lincke, J., Giannakaki-Zimmermann, H., Ebneter, A., Wolf, S., & Zinkernagel, M. S. (2017) · Ophthalmologica · doi:10.1159/000456083 · Cited by 8
Health-economic evaluation of fluocinolone acetonide 190 µg implant in people with diabetic macular edema
Holden, S. E., Currie, C. J., & Owens, D. R. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1366663 · Cited by 8
Therapie des diabetischen Makulaödems
Spital, G. (2018) · Der Diabetologe · doi:10.1007/s11428-018-0404-1 · Cited by 7
Stellungnahme der DOG, der RG und des BVA zur Therapie des diabetischen Makulaödems
(DOG), D. O. G., (RG), R. G. E. V., & (BVA), B. D. A. D. E. V. (2020) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1097-3440 · Cited by 8
Retinal thickness fluctuations in patients receiving fluocinolone acetonide implant for diabetic macular edema
Holden, S. E., Habib, M., & Currie, C. J. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1754183 · Cited by 8
Brain-derived neurotrophic factor in non-proliferative diabetic retinopathy with diabetic macular edema
JUN, Y. H., & Kim, S. T. (2020) · European Journal of Ophthalmology · doi:10.1177/1120672120944801 · Cited by 8
Galectins in the Pathogenesis of Common Retinal Disease
Caridi, B., Doncheva, D., Sivaprasad, S., & Turowski, P. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.687495 · Cited by 8
Preservation of the Photoreceptor Layer Following Subthreshold Laser Treatment for Diabetic Macular Edema as Demonstrated by SD-OCT
Soiberman, U., Goldstein, M., Pianka, P., Loewenstein, A., & Goldenberg, D. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-12607 · Cited by 8
Fluocinolone acetonide and its potential in the treatment of chronic diabetic macular edema
Haritoglou, C., Neubauer, & Kernt, M. (2013) · Clinical ophthalmology · doi:10.2147/opth.s34057 · Cited by 8
Major Topics in Type 1 Diabetes
Nunes, K. P. (2015) · InTech eBooks · doi:10.5772/59335 · Cited by 8
Intravitreal Steroid Implants in the Management of Retinal Disease and Uveitis
Logan, S. A., Weng, C. Y., & Carvounis, P. E. (2016) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000132 · Cited by 8
Costs of Managing Diabetic Macular Edema With Good Visual Acuity With Aflibercept, Laser, or Observation: DRCR Retina Network Protocol V
Hutton, D. W., Glassman, A. R., Stein, J. D., Bressler, N. M., & Sun, J. K. (2021) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2021.02.033 · Cited by 8
Self-citation
Combination of vascular endothelial growth factor inhibitors and laser therapy for diabetic macular oedema: a review
Mehta, H., Gillies, M. C., & Fraser‐Bell, S. (2016) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12757 · Cited by 8
Stellungnahme der DOG, der RG und des BVA zur Therapie des diabetischen Makulaödems
(DOG), D. O. G., (RG), R. G. E. V., & (BVA), B. D. A. D. E. V. (2020) · Der Ophthalmologe · doi:10.1007/s00347-019-01015-2 · Cited by 14
Diabetic retinopathy—recommendations for screening and treatment
Pedrini, A., Nowosielski, Y., & Rehák, M. (2025) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-025-01088-6 · Cited by 7
Patients’ experiences before starting anti-VEGF treatment for sight-threatening diabetic macular oedema: A qualitative interview study
Granström, T., Forsman, H., Brorsson, A. L., Granstam, E., & Leksell, J. K. (2017) · Nordic journal of nursing research · doi:10.1177/2057158517709409 · Cited by 7
Recurrent Diabetic Macular Edema: What to Do
Gonçalves, R., Teixeira, C., & Coelho, P. (2017) · Case Reports in Ophthalmology · doi:10.1159/000480119 · Cited by 7
EFFICACY AND SAFETY OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOCUSING ON PATIENTS WITH DIABETIC MACULAR EDEMA FROM JAPAN
Terasaki, H., Shiraki, K., Ohji, M., Metzig, C., Schmelter, T., Zeitz, O., Sowade, O., Kobayashi, M., Vitti, R., Berliner, A. J., et al. (2018) · Retina · doi:10.1097/iae.0000000000002100 · Cited by 7
Diabetisches Makulaödem
Barth, T., & Helbig, H. (2021) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1545-9656 · Cited by 7
Restoration of Photoreceptor Outer Segments up to 24 Months after Pars Plana Vitrectomy in Patients with Diabetic Macular Edema
Miyamoto, N., Ishida, K., & Kurimoto, Y. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.01.017 · Cited by 7
Intravitreal Ranibizumab in Diabetic Macular Edema: Long-Term Outcomes
Zucchiatti, I., & Bandello, F. M. (2017) · Developments in ophthalmology · doi:10.1159/000460496 · Cited by 7
The real life data of ranibizumab use among the diabetic macular edema patients in Turkey: Documenting the improvement with clinical optimization during three consecutive years
Özkaya, A., Ozveren, M., & Demircan, A. (2018) · Saudi Journal of Ophthalmology · doi:10.1016/j.sjopt.2018.04.005 · Cited by 7
Implantable anti-angiogenic scaffolds for treatment of neovascular ocular pathologies
Sarkar, B., Siddiqui, Z., Kim, K. K., Nguyen, P. K., Reyes, X., McGill, T. J., & Kumar, V. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00753-0 · Cited by 7
Optical Coherence Tomography Patterns in Diabetic Macular Edema can Predict the Effectiveness of Intravitreal Bevacizumab Combined with Macular Photocoagulation
Telbizova-Radovanova, K. (2014) · Journal of Clinical & Experimental Ophthalmology · doi:10.4172/2155-9570.1000355 · Cited by 7
Experimental verification of subthreshold laser therapy using conventional pattern scan laser
Shiraya, T., Kato, S., Araki, F., Ueta, T., Abe, H., & Asai, N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184392 · Cited by 6
The sterility, stability and efficacy of repackaged ziv-aflibercept for intravitreal administration
Juhong, J., Pongsachareonnont, P. F., Somkijrungroj, T., Mavichak, A., Varadisai, A., Chariyavilaskul, P., Chatsuwan, T., Suttichet, T. B., & Kulvichit, K. (2022) · Scientific Reports · doi:10.1038/s41598-022-06831-2 · Cited by 6
Is Laser Still Important in Diabetic Macular Edema as Primary or Deferral Therapy
Parodi, M. B., & Bandello, F. M. (2017) · Developments in ophthalmology · doi:10.1159/000459696 · Cited by 6
Anti-VEGF Treatment of Diabetic Macular Edema: Two-Year Visual Outcomes in Routine Clinical Practice
Urbančič, M., Klobučar, P., Zupan, M., Urbančič, K., & Lavrič, A. (2020) · Journal of Ophthalmology · doi:10.1155/2020/6979758 · Cited by 6
Three versus five intravitreal aflibercept injections as the initial loading phase in the treatment of diabetic macular edema: one-year results
Çakır, A., Erden, B., Bölükbaşı, S., Sever, Ö., Erkul, S. Ö., Osmanbaşoğlu, Ö. A., Karaca, G., & Elçioğlu, M. N. (2020) · Arquivos Brasileiros de Oftalmologia · doi:10.5935/0004-2749.20200078 · Cited by 6
Real-World Anti-Vascular Endothelial Growth Factor Therapy Outcomes in Myopic Choroidal Neovascularization
Bhatia, D., Mehta, A., DaCosta, J., Crothers, O., & Talks, J. S. (2021) · Clinical ophthalmology · doi:10.2147/opth.s311816 · Cited by 6
Diabetische Makulopathie
Haritoglou, C., Kernt, M., & Wolf, A. (2015) · Der Ophthalmologe · doi:10.1007/s00347-015-0127-2 · Cited by 6
Risk Factors for Refractory Diabetic Macular Oedema after Sub-Tenon’s Capsule Triamcinolone Acetonide Injection
Oshitari, T., Kitamura, Y., Nonomura, S., Arai, M., Takatsuna, Y., Sato, E., Baba, T., & Yamamoto, S. (2015) · Journal of Ophthalmology · doi:10.1155/2015/195737 · Cited by 6
Vitreomacular interface after anti-VEGF injections in diabetic macular edema
Veloso, C. E. D. R., Brocchi, D. N., Singh, R. P., & Nehemy, M. B. (2021) · International Journal of Retina and Vitreous · doi:10.1186/s40942-021-00295-8 · Cited by 6
Triamcinolone as an adjunct to the combination of anti-VEGF for the management of diabetic macular edema
Yu, Y., Li-bin, C., Xia, H., & Li, X. (2021) · International Journal of Ophthalmology · doi:10.18240/ijo.2021.06.12 · Cited by 6
Screening for diabetic retinopathy: the optometrist’s perspective
Aldebasi, Y. H., Reddy, P. A., Nair, V., & Ahmad, M. (2015) · Clinical Optometry · doi:10.2147/opto.s36603 · Cited by 6
Should we still be performing macular laser for non-centre involving diabetic macular oedema? Yes
Zur, D., & Loewenstein, A. (2021) · Eye · doi:10.1038/s41433-021-01793-7 · Cited by 6
Does dexamethasone implant combination with aflibercept monotherapy affect one-year outcomes in treatment-naive diabetic macular edema with inflammatory biomarkers?
Özsaygılı, C., & Bayram, N. (2024) · International Ophthalmology · doi:10.1007/s10792-024-02963-8 · Cited by 5
Efficacy, safety, and cost-effectiveness of biosimilars of bevacizumab in näive patients with diabetic macular edema
Virani, S., Bhatiwal, A., & Rewri, P. (2024) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_58_24 · Cited by 5
Wann wird heute noch gelasert?
Enders, P., Schaub, F., & Fauser, S. (2017) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/s-0042-123831 · Cited by 5
Advances in Teleophthalmology
Irrcher, I., & ten Hove, M. (2019) · Advances in Ophthalmology and Optometry · doi:10.1016/j.yaoo.2019.04.019 · Cited by 5
Long‐term follow‐up of antivascular endothelial growth factor treatment for diabetic macular oedema: a four‐year real‐world study
Granstam, E., Rosenblad, A., Raghib, A. M., Granström, T., Eriksson, J. W., Olinder, A. L., & Leksell, J. K. (2019) · Acta Ophthalmologica · doi:10.1111/aos.14290 · Cited by 6
The effect of posterior sub-Tenon’s capsule triamcinolone acetonide injection to that of pars plana vitrectomy for diabetic macular edema
Oshitari, T., Nonomura, S., Arai, M., Sato, E., Takatsuna, Y., Baba, T., & Yamamoto, S. (2014) · Clinical ophthalmology · doi:10.2147/opth.s59849 · Cited by 5
Management of Diabetic Retinopathy and Other Ocular Complications in Type 1 Diabetes
Berco, E., Rappoport, D., Pollack, A., Kleinmann, G., & Greenwald, Y. (2015) · InTech eBooks · doi:10.5772/61276 · Cited by 5
A cost analysis comparing continued 3-year aflibercept monotherapy versus a switch from aflibercept to the fluocinolone acetonide intravitreal implant in phakic patients with chronic diabetic macular edema
Raman, V. (2018) · Expert Review of Ophthalmology · doi:10.1080/17469899.2018.1523720 · Cited by 5
Effect of Alternate Treatment with Intravitreal Anti-Vascular Endothelial Growth Factor and Steroid for Treatment-Naive Diabetic Macular Edema in a Real-Life Setting
Lee, J. Y., Lee, S.-Y., Kim, J. Y., Lee, H. J., Jeong, J. H., & Ma, D. J. (2020) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2020.0012 · Cited by 5
Treatment of macular diseases: an overview of key randomized clinical trials
Валерьевич, Б. Е., Morozova, O. V., & Береснева, Н. С. (2022) · Russian Ophthalmological Journal · doi:10.21516/2072-0076-2021-14-4-137-148 · Cited by 5
Visual outcome of laser treatment in diabetic macular edema: Study from an Urban Diabetes Care Center
Alvi, R., Memon, M. S., Shera, A. S., Mumtaz, S. N., Shaikh, S. A., & Fahim, M. F. (2016) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.325.10597 · Cited by 5
Adjunct Intravitreous Triamcinolone Acetonide in the Treatment of Diabetic Macular Edema with Anti-VEGF Agents
Garoon, R. B., Coffee, R. E., Jiang, L., Weng, C. Y., & Carvounis, P. E. (2016) · Journal of Ophthalmology · doi:10.1155/2016/5282470 · Cited by 5

Authors: Elman, M. J., Ayala, A., Bressler, N. M., Browning, D., Flaxel, C. J., Glassman, A. R., Jampol, L. M., & Stone, T. W.
Affiliations: Elman Retina Group (US)
Jaeb Center for Health Research (US)
Johns Hopkins University (US)
Charlotte Eye Ear Nose & Throat Associates (US)
Northwestern University (US)
Retina Associates of Kentucky (US)
Corresponding author: Ayala, Allison
ORCID: Elman, Michael J.
Ayala, Allison
Bressler, Neil M.
Browning, David
Flaxel, Christina J.
Glassman, Adam R.
Jampol, Lee M.
Venue: Ophthalmology
Publisher: Elsevier BV
Published: 2015-02
Volume: 122
Issue: 2
Pages: 375-381
ISSN: 0161-6420 (ISSN-L)
DOI: 10.1016/j.ophtha.2014.08.047
PMC: PMC4520307
OpenAlex: W1980342089
Cited by: 562
References: 10
Citations by year: 2026: 8 · 2025: 18 · 2024: 22 · 2023: 20 · 2022: 35 · 2021: 39 · 2020: 55 · 2019: 41 · 2018: 45 · 2017: 79 · 2016: 72 · 2015: 73
FWCI: 79.09
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Ophthalmology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Eye Institute (EY14231, EY-14229, EY18817, EY023207, U10EY018817, U10EY014229, U10EY023207, U10EY014231, UG1EY014231)
Topics: Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords: diabetic macular edema, ranibizumab, intravitreal injection, best-corrected visual acuity, long-term visual outcomes, anti-VEGF therapy, vision loss, treatment duration extension, retinal laser treatment, anti-angiogenic therapy, treatment burden reduction
MeSH terms: Ranibizumab, Aged, Combined Modality Therapy, Diabetic Retinopathy, Female, Humans, Macular Edema, Male, Middle Aged, Visual Acuity, Treatment Outcome, Laser Coagulation, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Intravitreal Injections, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks